Cardioprotection: the role of beta-blocker therapy.

Brent M. Egan, Jan Basile, Robert J Chilton, Jerome D. Cohen

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Randomized controlled clinical trials document that beta blockers reduce cardiovascular morbidity and mortality, particularly sudden death, in patients with hypertension, heart failure, and post-myocardial infarction. The benefits of beta blockers extend across the boundaries of age, gender, and ethnicity, and include diabetic patients with heart failure and/or previous myocardial infarction. Unfortunately, beta blockers remain underutilized in many high-risk patients who would likely benefit from their use. This paper reviews the protective role of beta blockade in the primary and secondary prevention of cardiovascular events and examines some of the potential barriers to appropriate beta blocker use in patients with compelling indications.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume7
Issue number7
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Heart Failure
Myocardial Infarction
Primary Prevention
Therapeutics
Sudden Death
Secondary Prevention
Randomized Controlled Trials
Hypertension
Morbidity
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Egan, B. M., Basile, J., Chilton, R. J., & Cohen, J. D. (2005). Cardioprotection: the role of beta-blocker therapy. Journal of clinical hypertension (Greenwich, Conn.), 7(7), 409-416.

Cardioprotection : the role of beta-blocker therapy. / Egan, Brent M.; Basile, Jan; Chilton, Robert J; Cohen, Jerome D.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 7, No. 7, 07.2005, p. 409-416.

Research output: Contribution to journalArticle

Egan, BM, Basile, J, Chilton, RJ & Cohen, JD 2005, 'Cardioprotection: the role of beta-blocker therapy.', Journal of clinical hypertension (Greenwich, Conn.), vol. 7, no. 7, pp. 409-416.
Egan, Brent M. ; Basile, Jan ; Chilton, Robert J ; Cohen, Jerome D. / Cardioprotection : the role of beta-blocker therapy. In: Journal of clinical hypertension (Greenwich, Conn.). 2005 ; Vol. 7, No. 7. pp. 409-416.
@article{b93496759c3a40a5a9118a103c81e741,
title = "Cardioprotection: the role of beta-blocker therapy.",
abstract = "Randomized controlled clinical trials document that beta blockers reduce cardiovascular morbidity and mortality, particularly sudden death, in patients with hypertension, heart failure, and post-myocardial infarction. The benefits of beta blockers extend across the boundaries of age, gender, and ethnicity, and include diabetic patients with heart failure and/or previous myocardial infarction. Unfortunately, beta blockers remain underutilized in many high-risk patients who would likely benefit from their use. This paper reviews the protective role of beta blockade in the primary and secondary prevention of cardiovascular events and examines some of the potential barriers to appropriate beta blocker use in patients with compelling indications.",
author = "Egan, {Brent M.} and Jan Basile and Chilton, {Robert J} and Cohen, {Jerome D.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "7",
pages = "409--416",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Cardioprotection

T2 - the role of beta-blocker therapy.

AU - Egan, Brent M.

AU - Basile, Jan

AU - Chilton, Robert J

AU - Cohen, Jerome D.

PY - 2005/7

Y1 - 2005/7

N2 - Randomized controlled clinical trials document that beta blockers reduce cardiovascular morbidity and mortality, particularly sudden death, in patients with hypertension, heart failure, and post-myocardial infarction. The benefits of beta blockers extend across the boundaries of age, gender, and ethnicity, and include diabetic patients with heart failure and/or previous myocardial infarction. Unfortunately, beta blockers remain underutilized in many high-risk patients who would likely benefit from their use. This paper reviews the protective role of beta blockade in the primary and secondary prevention of cardiovascular events and examines some of the potential barriers to appropriate beta blocker use in patients with compelling indications.

AB - Randomized controlled clinical trials document that beta blockers reduce cardiovascular morbidity and mortality, particularly sudden death, in patients with hypertension, heart failure, and post-myocardial infarction. The benefits of beta blockers extend across the boundaries of age, gender, and ethnicity, and include diabetic patients with heart failure and/or previous myocardial infarction. Unfortunately, beta blockers remain underutilized in many high-risk patients who would likely benefit from their use. This paper reviews the protective role of beta blockade in the primary and secondary prevention of cardiovascular events and examines some of the potential barriers to appropriate beta blocker use in patients with compelling indications.

UR - http://www.scopus.com/inward/record.url?scp=33644874331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644874331&partnerID=8YFLogxK

M3 - Article

C2 - 16015051

AN - SCOPUS:33644874331

VL - 7

SP - 409

EP - 416

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 7

ER -